Table 2. Association between EGFR and mTOR pathways and clinical–pathological parameters (n=107).
EGFR | p-ERK | p-AKT | p-mTOR | p-p70s6K | ChemoTx | pT-stage | pN-stage | DFS | OS | |
---|---|---|---|---|---|---|---|---|---|---|
EGFR | P=0.02 | NS | P=0.0001 | NS | P=0.038 | NS | NS | NS | NS | |
p-ERK | P=0.02 | P=0.0001 | NS | NS | NS | NS | NS | NS | NS | |
p-AKT | NS | P=0.0001 | NS | NS | NS | NS | NS | NS | NS | |
p-mTOR | P=0.0001 | NS | NS | P=0.001 | NS | P=0.048 | NS | NS | NS | |
p-p70s6K | NS | NS | NS | P=0.001 | NS | P=0.02 | P=0.001 | NS | NS |
Abbreviations: DFS=disease-free survival; EGFR=epidermal growth factor receptor; mTOR=mammalian target of rapamycin; NS=not significant; OS=overall survival; p-AKT=phosphorylated AKT; p-ERK=phosphorylated extracellular signal-regulated kinase.